Restructuring for Biopharmaceutical Success

A late-breaking poster presented at ASGCT 2025 described the enhanced central nervous system transduction and safety of the vector.

This podcast explores the challenges of and the progress made so far by the biopharma industry toward alternative drug delivering methods for biologic drugs.

Tevard's tRNA therapy appears to restore full-length dystrophin and motor function in a Duchenne muscular dystrophy model, showing promise for nonsense mutation treatments.

Hanns-Christian Mahler and Andrea Allmendinger from ten23 health will discuss some key aspects of biologic drug development and manufacturing.

According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.

As more originator biologics lose patent exclusivity in the next decade, a healthy biosimilars pipeline is necessary but requires market support.